Overview

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this Multiple Ascending Dose (MAD) study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
Phase:
Phase 2
Details
Lead Sponsor:
AL-S Pharma